High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
| العنوان: | High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series |
|---|---|
| المؤلفون: | Rossella Hakim, Michela Pierini, Elisabetta Setola, Lorenzo D'Ambrosio, Daniel Vanel, Piero Picci, Ymera Pignochino, Marilena Cesari, Giovanni Grignani, Davide Maria Donati, Stefano Ferrari, Emanuela Marchesi, Alessandro Comandone, Alberto Righi, Anna Paioli, Alessandra Longhi, Emanuela Palmerini |
| المساهمون: | Palmerini, Emanuela, Setola, Elisabetta, Grignani, Giovanni, D'Ambrosio, Lorenzo, Comandone, Alessandro, Righi, Alberto, Longhi, Alessandra, Cesari, Marilena, Paioli, Anna, Hakim, Rossella, Pierini, Michela, Marchesi, Emanuela, Vanel, Daniel, Pignochino, Ymera, Donati, Davide Maria, Picci, Piero, Ferrari, Stefano |
| المصدر: | Cells, Vol 9, Iss 2389, p 2389 (2020) Cells Volume 9 Issue 11 |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, medicine.medical_treatment, pediatric bone tumor, Poly (ADP-Ribose) Polymerase-1, high-grade bone sarcoma, Gene mutation, chemotherapy, Gastroenterology, PARP1, 0302 clinical medicine, Medicine, Child, lcsh:QH301-705.5, Ifosfamide, ifosfamide, Standard treatment, High-Throughput Nucleotide Sequencing, General Medicine, sequencing, Middle Aged, Treatment Outcome, Local, 030220 oncology & carcinogenesis, Osteosarcoma, Female, Drug, medicine.drug, musculoskeletal diseases, Adult, medicine.medical_specialty, Adolescent, Bone Neoplasms, Article, Dose-Response Relationship, 03 medical and health sciences, Young Adult, Internal medicine, osteosarcoma, Humans, neoplasms, Aged, Retrospective Studies, Cisplatin, Chemotherapy, Dose-Response Relationship, Drug, business.industry, pediatric bone tumors, Doxorubicin, Methotrexate, Mutation, Neoplasm Recurrence, Local, Retrospective cohort study, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, lcsh:Biology (General), business |
| الوصف: | Background: The evidence on high-dose ifosfamide (HD-IFO) use in patients with relapsed osteosarcoma is limited. We performed a retrospective study to analyze HD-IFO activity. Methods: Patients with osteosarcoma relapsed after standard treatment [methotrexate, doxorubicin, cisplatin +/&minus ifosfamide (MAP+/&minus I)] with measurable disease according to RECIST1.1 were eligible to ifosfamide (3 g/m2/day) continuous infusion (c.i.) days 1&ndash 5 q21d. RECIST1.1 overall response rate (ORR) (complete response (CR) + partial response (PR)), progression-free survival at 6-month (6m-PFS), duration of response (DOR), and 2-year overall survival (2y-OS) were assessed. PARP1 expression and gene mutations were tested by immunohistochemistry and next-generation sequencing. Results: 51 patients were included. ORR was 20% (1 CR + 9 PR). Median DOR was 5 months (95%CI 2&ndash 7). Median PFS, 6m-PFS, OS, and 2y-OS were 6 months (95%CI 4&ndash 9), 51%, 15 months (10&ndash 19), and 30%, respectively. A second surgical complete remission (CR2) was achieved in 26 (51%) patients. After multivariate analysis, previous use of ifosfamide (HR 2.007, p = 0.034) and CR2 (HR 0.126, p < 0.001) showed a significant correlation with PFS and OS, respectively. No significant correlation was found between outcomes and PARP1 or gene mutations. Conclusions: HD-IFO should be considered as the standard first-line treatment option in relapsed osteosarcoma and control arm of future trial in this setting. |
| وصف الملف: | ELETTRONICO; application/pdf |
| اللغة: | English |
| تدمد: | 2073-4409 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c690466a4ecbfad593bdeace39a37bTest https://www.mdpi.com/2073-4409/9/11/2389Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....95c690466a4ecbfad593bdeace39a37b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20734409 |
|---|